Literature DB >> 5500701

Growth inhibition of rat mammary carcinoma and endocrine changes produced by 2-Br-alpha-ergocryptine, a suppressor of lactation and nidation.

J C Heuson, C Waelbroeck-van Gaver, N Legros.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5500701     DOI： 10.1016/0014-2964(70)90031-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  6 in total

1.  Suppression of puerperal lactation with an ergot alkaloid: a double-blind study.

Authors:  L Varga; P M Lutterbeck; J S Pryor; R Wenner; H Erb
Journal:  Br Med J       Date:  1972-06-24

Review 2.  Growth hormone, the insulin-like growth factor axis, insulin and cancer risk.

Authors:  Peter E Clayton; Indraneel Banerjee; Philip G Murray; Andrew G Renehan
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

3.  Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

Authors:  S Li; M Lepage; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Primate mammary development. Effects of hypophysectomy, prolactin inhibition, and growth hormone administration.

Authors:  D L Kleinberg; W Niemann; E Flamm; P Cooper; G Babitsky; Q Valensi
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

5.  Influence of chronic treatment with 2-bromo-alpha-ergocryptine (CB-154) on the reproductive and lactational performance of the C3H/HeJ female mouse.

Authors:  C W Welsh; L K Morford
Journal:  Experientia       Date:  1974-11-15

6.  Effect of prolactin and bromocriptine on growth of transplanted hormone-dependent mouse mammary tumours.

Authors:  P Briand; S M Thorpe; J L Daehnfeldt
Journal:  Br J Cancer       Date:  1977-06       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.